TCGA-E2-A1B5-01A-21R-A12P-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 33
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.570
- INTERFERON_GAMMA_RESPONSE+0.500
- INTERFERON_ALPHA_RESPONSE+0.440
- IL6_JAK_STAT3_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.390
- COMPLEMENT+0.370
- KRAS_SIGNALING_UP+0.370
- IL2_STAT5_SIGNALING+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
Top 10 suppressed
- MITOTIC_SPINDLE-0.480
- G2M_CHECKPOINT-0.470
- E2F_TARGETS-0.430
- GLYCOLYSIS-0.300
- MYC_TARGETS_V2-0.280
- PROTEIN_SECRETION-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- APICAL_JUNCTION-0.200
- ESTROGEN_RESPONSE_EARLY-0.190
- CHOLESTEROL_HOMEOSTASIS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R13 | — | — | 0.871 |
| 2 | SRR25617878 | — | D | 0.869 |
| 3 | ad2bbb19-6d02-480f-b011-d4327c3c5607 | — | — | 0.868 |
| 4 | SRR8518388 | — | D | 0.850 |
| 5 | TCGA-BH-A0B6-01A-11R-A19W-07 | — | D | 0.845 |
| 6 | da7cbc0a-95dc-4303-a5dd-75857c066f3b | — | — | 0.840 |
| 7 | TCGA-67-3773-01A-01R-0946-07 | — | cohortA1 | 0.835 |
| 8 | MNG1252 | — | — | 0.832 |
| 9 | f5760366-59eb-417d-a935-3f78e999dd42 | — | — | 0.829 |
| 10 | SAMN03290925 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |